Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEREO: Osimertinib and SBRT in Oligo-metastatic EGFR-mutant NSCLC
NCT04908956Phase 2Terminated
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoints: Rate of grade ≥2 pneumonitis at 18 months and Progression-Free Survival at 44 months. Started Aug 2022; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04908956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908956.